Gastrointestinal stromal tumours: origin and molecular oncology.

摘要: Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of personalized treatment cancer patients. The nearly simultaneous discovery biomarker that is reflective their origin and presence gain-of-function kinase mutations in these set stage more accurate diagnosis inhibitor therapy. Subsequent studies genotype phenotype have led to molecular classification GIST optimization on basis subtype. study drug-resistant has advanced our understanding biology, enabling novel inhibitors. Further improvements may require targeting stem cell populations and/or additional genomic events.